The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.
 
Shunsuke Kondo
Honoraria - Chugai Pharma; Eisai; Incyte
Consulting or Advisory Role - Takeda
Speakers' Bureau - Incyte
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Eisai (Inst); Lilly (Inst)
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sumitomo Dainippon Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Satoru Iwasa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Ono Pharmaceutical; Sysmex
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Yuri Ueda
Honoraria - Merck; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb
 
Satoshi Nagao
Employment - Eisai
 
Takayuki Kimura
Employment - Eisai
 
Ippei Suzuki
Employment - Eisai
 
Nozomi Hayata
Employment - Eisai
 
Toshiyuki Tamai
Employment - Eisai
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Janssen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)